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Abstract
Background: Fatigue is a major clinical problem in many patients with primary biliary cirrhosis
(PBC) and primary sclerosing cholangitis (PSC). An effective treatment has not been defined.
Recently, a large proportion of patients with these diseases was found to have symptoms of
depression. Because fatigue is a frequent symptom of depression and there is some evidence that
treatment with an antidepressant improves fatigue in patients with fibromyalgia, we hypothesised
that the antidepressant fluvoxamine might improve fatigue related to PBC and PSC.
Methods: Fatigued patients were randomised to receive fluvoxamine (75 mg BID) or placebo for
a six-week period. Fatigue and quality of life were quantified using a visual analogue scale, the Fisk
Fatigue Severity Scale, the Multidimensional Fatigue Inventory and the SF-36.
Results: Seventeen and 16 patients were allocated to fluvoxamine and placebo, respectively. There
was no statistically significant beneficial effect of fluvoxamine on fatigue or quality of life. The median
VAS scores in the fluvoxamine and placebo groups were 7.40 and 7.45 at day 0, 6.9 and 7.15 at day
14, 7.45 and 7.65 at day 42 and 7.8 and 8.0 four weeks after treatment discontinuation.
Conclusion: We found no evidence for a beneficial effect of fluvoxamine on fatigue in these
patients with cholestatic liver disease and severe chronic fatigue.
Background
Primary biliary cirrhosis (PBC) and primary sclerosing
cholangitis (PSC) are chronic cholestatic liver diseases
with a relatively favourable prognosis for most patients
[1,2]. Fatigue is now recognised as a major clinical prob-
lem in PBC, with a reported prevalence of up to 85% [3].
Although fatigue has not been studied extensively in PSC,
it is a problem in many of these patients as well [4]. There
have been no reports of drugs or other treatment modali-
ties with a beneficial effect on fatigue associated with
these diseases, and although the widely used drug ursode-
oxycholic acid improves the biochemical abnormalities in
these diseases, an effect on fatigue has not been shown
[5,6].
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Recent studies suggest that 45–72% of patients may have
a depressive disorder [3,5]. Fatigue is a frequent symptom
of depression. We hypothesised that common mecha-
nisms may be involved in the aetiology of both fatigue
and depression or that fatigue could be a symptom of a
depressive disorder in PBC and PSC. If this would be true,
antidepressive drugs could have a beneficial effect on
fatigue and potentially also on overall quality of life. Thus,
the present study aimed to evaluate the effects of an anti-
depressant on fatigue and quality of life in PBC and PSC.
The antidepressant fluvoxamine (a selective serotonin re-
uptake inhibitor, SSRI) was chosen because of several rea-
sons. First, fluvoxamine is one of the oldest SSRI's, and the
risk of unexpected side-effects was therefore low. Second,
there was extensive local experience with this particular
drug. Third, there is a documented correlation between
serum concentrations and effects for fluvoxamine, which
could be used in future studies using this drug.
Methods
Participants
All patients visiting the outpatient clinic of our hospital
with a diagnosis of PBC or PSC and self-reported signifi-
cant fatigue for which the patient was willing to receive
treatment were invited to participate. Patients with a diag-
nosis of depression or other psychiatric disorder, any
change in medication in the past three months, incom-
plete understanding of the Dutch language, pregnancy,
current lactation or lack of adequate contraception, Child-
Pugh score of ≥6 or receiving other study medication in
the preceding 6 months were excluded. The Beck Depres-
sion Inventory was used to screen for the presence of
depression, and in patients with a score >10 a psychiatric
evaluation using the SADS DSM-IV was performed [7].
Written informed consent was obtained in all patients.
The institutional review board approved the study.
Treatment
Patients were treated with identical capsules containing
75 mg of fluvoxamine or placebo. They were instructed to
take a capsule in the evening before sleeping on the first
two days, and to add one capsule in the morning starting
on day three and to continue this treatment regimen of 75
mg BID for a total period of six weeks. This dose is a
widely used dose for the treatment of depression. Since
previous data on the effects on fatigue were lacking, this
dose was used in the present study. Patients were
instructed to contact the trial co-ordinators in case of side
effects.
Objectives
The aim of the study was to assess the efficacy of fluvox-
amine in the treatment of fatigue associated with PBC or
PSC.
Outcomes
The primary outcome was an improvement in fatigue, as
measured by a visual analogue scale (VAS), the Fisk
Fatigue Severity Scale (FFSS) [8] and the Multidimen-
sional Fatigue Inventory (MFI) [9]. The FFSS has been pre-
viously validated for assessing fatigue in PBC [10]. The
VAS consisted of a 10-cm line with on one end 'no fatigue
at all during the last month' and on the other end 'extreme
fatigue during the last month'. Patients were asked to indi-
cate the severity of fatigue by placing a marking on the
line. A higher score represents increased fatigue in these
three outcome measures. Secondary outcomes were
changes in quality of life, assessed by the SF-36 question-
naire [11], changes in pruritus using a VAS and changes in
laboratory tests. The VAS for pruritus consisted of a 10-cm
line with on one end 'no pruritus at all during the last
month' and on the other end 'severe pruritus during the
last month'. At entry and after 42 days the following tests
were performed: FFSS, MFI, SF-36, VAS for fatigue and
pruritus, total serum bilirubin, albumin, gamma-GT, alka-
line phosphatase (APh), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), cholesterol, immu-
noglobulin G (IgG), immunoglobulin M (IgM), pro-
thrombin time (PT), antithrombin-III (AT-III),
haemoglobin, leukocyte and platelet count. At 14 days,
the FFSS, MFI and serum bilirubin, ALT and APh were
repeated. At day 70, the MFI, FFSS and the VAS for fatigue
and pruritus were obtained.
Sample Size
A formal power calculation was precluded by absence of
data on the efficacy of fluvoxamine in the treatment of
fatigue associated with PBC or PSC. In order to detect an
effect similar to the expected therapeutic effect of fluvox-
amine in depression (25% improvement in the placebo-
group and 75% in the fluvoxamine-group), with a power
of 80% and assuming a drop-out rate of 5%, it was calcu-
lated that 40 patients needed to be recruited (Stata 5.0,
Stata Corporation, College Station, Texas, USA).
Randomisation
Patients were allocated to a serial number (by authors PB
or HB) corresponding to a previously prepared package of
capsules. The capsules containing fluvoxamine or placebo
were prepared by the hospital pharmacy. The packages
were numbered according to a computer generated ran-
domisation list prepared by the trial statistician (BH).
Thus, both patients and those assessing the outcomes
were blinded to group assignment. Patients were stratified
for disease (PBC or PSC). Opaque, closed envelopes con-
taining information on the allocated treatment for each
patient number were prepared for medical emergencies.BMC Gastroenterology 2004, 4:13 http://www.biomedcentral.com/1471-230X/4/13
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Trial profile Figure 1
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Statistical methods
Data were analysed according to both the intention-to-
treat and the per-protocol principle. Differences between
groups were planned to be tested with the χ2 and Student's
t-test. However, in part because of the lower than expected
patient recruitment and the higher than expected drop-
out rate, a normal data distribution was not present for
most variables. Therefore, it was decided that the Mann-
Whitney test would be used for testing differences
between groups. Statistical tests were two-tailed. P-values
of 0.05 or less were considered statistically significant. In
the analyses where the multiple time points were com-
pared, a p-value of <0.05 divided by 3 (p < 0.017) was
considered statistically significant. Subgroup analyses
including only patients with PBC and PSC were per-
formed using the same statistical methods. Statistical
analyses were performed using SPSS (Version 9.0, SPSS
Inc, Chicago, IL, U.S.A).
Results
Recruitment, allocation and participants flow
Patients were included between October 2001 and June
2002. Five patients (29%) in the fluvoxamine group and
2 patients (13%) in the placebo group discontinued treat-
ment because of side effects (p = 0.40). All randomised
patients were included in the intention-to-treat analysis,
and all patients completing the six weeks treatment period
were included in the per-protocol analysis (Figure 1).
Baseline characteristics
Of the 82 patients screened for inclusion, 33 met all inclu-
sion and exclusion criteria and gave their informed con-
sent to participate in the trial. Although 18/33 (55%)
patients had a Beck Depression Inventory score >10
points, suggesting the presence of depression, additional
psychiatric evaluation (EO and WB) according to the
DSM-IV found no evidence for depression in any of these
cases. In three patients not suitable for inclusion in the
present trial a diagnosis of depression was made accord-
ing to the DSM-IV criteria. One patient had been diag-
nosed with depression thirteen years before entry;
however psychiatric evaluation found no evidence for
depression at the time of entry. Of the 33 patients, 16 were
allocated to the placebo group and 17 to the fluvoxamine
group. General baseline data and questionnaire results are
shown in tables 1 and 2, respectively. All patients had
been fatigued during at least two years; none had renal
failure, chronic anaemia or serum electrolyte abnormali-
ties. One patient (fluvoxamine group) was receiving treat-
ment for hypothyroidism and was already fatigued before
thyroid dysfunction developed and thyroid function was
documented to be normal. In all other patients thyroid
function was normal. Five patients (4 in the fluvoxamine
group) were using β-blockers; in all cases chronic fatigue
had been present before initiation of this therapy. Patients
in the fluvoxamine group had significantly higher scores
in the cognitive and social domains of the FFSS (p = 0.04
for both domains). Differences for all other baseline vari-
ables were non-significant.
Outcomes
Analysis on intention-to-treat basis (17 and 16 patients in
the fluvoxamine and placebo group, respectively) yielded
no significant differences in response between the fluvox-
amine and the placebo group with respect to the primary
outcome measures, the fatigue visual analogue score, MFI
and FFSS (Table 3). Per-protocol analysis (12 patients and
14 patients in the fluvoxamine and placebo group, respec-
tively) of the same outcomes showed no significant differ-
ences except for a borderline significant difference in the
general fatigue domain of the MFI in favour of the placebo
group (p = 0.04). The results of the intention-to-treat
analysis with respect to the fatigue VAS scores are shown
in figure 2. Analysis (intention-to-treat) of changes in SF-
Table 1: Baseline characteristics (general)
Fluvoxamine N = 17 Placebo N = 16 P-value
Male/Female 4/13 6/10 0.38
PBC/PSC 12/5 10/6 0.57
Age (median) 51 54 0.38
Pruritus (yes/no) 9/8 8/8 0.87
UDCA dose (median, mg/day) 750 900 0.14
Previous depressive disorder (yes/no) (0/17) (1/15) 0.30
Weight (median, kg) 67 71 0.95
Length (median, cm) 173 171 0.67
Body Mass Index (median) 24.2 24.6 0.61
Haemoglobin (mmol/l, median) 8.3 8.8 0.21
Bilirubin (µmol/l, median) 13 11.5 0.83
Alkaline Phosphatase (U/l, median) 137 192 0.36
ALT (U/l, median) 42 43 0.55
Albumin (U/l, median) 42 41.5 0.81
Laboratory reference values: haemoglobin 7.5–9.5 mmol/l, bilirubin 0–16 µmol/l, alkaline phosphatase 0–119 U/l, ALT 0–30 U/l, albumin 35–50 g/l.BMC Gastroenterology 2004, 4:13 http://www.biomedcentral.com/1471-230X/4/13
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36 scores revealed no differences between treatment
groups. No significant difference in pruritus was found
according to VAS scores at entry and at 6 weeks in either
group. The only (borderline) significant difference in the
laboratory test results was for serum alkaline phosphatase
at day 42 and day 0, attributable to a significant decrease
at 42 days in the placebo group (p = 0.03). Subgroup anal-
ysis of only patients with PBC or PSC showed no signifi-
cant differences between the fluvoxamine and placebo
groups (Tables 4 and 5). In addition, no significant differ-
ences in reponse were found between men and women.
One patient treated with fluvoxamine who suffered from
fatigue for many years prior to inclusion in the present
Table 2: Baseline values of outcome measures
Fluvoxamine (n = 17) Placebo (n = 16) P-value
VAS Fatigue 7.40 7.45 0.91
VAS Pruritus 3.50 1.15 0.33
Beck Depression Inventory 11.0 10.5 0.45
FFSS
Physical Domain 24.0 16.5 0.25
Cognitive Domain 15.0 9.0 0.04
Social Domain 37.0 22.5 0.04
MFI
General Fatigue 18.0 17.5 0.78
Physical Fatigue 16.0 14.0 0.22
Reduction in Activity 15.0 13.0 0.30
Reduction in Motivation 13.0 10.0 0.17
Mental Fatigue 13.0 13.0 0.90
SF-36
Physical Functioning 65.0 70.0 0.47
Role Functioning Physical 25.0 25.0 0.35
Bodily Pain 62.0 62.0 0.55
General Health 40.0 35.0 0.63
Vitality 45.0 40.0 0.64
Social Functioning 62.5 62.5 0.34
Role Emotional Functioning 100.0 66.7 0.46
Mental Health 56.0 60.0 0.28
Reported Health Transition 4.0 4.0 1.00
All results are expressed as median scores.
Table 3: Primary outcomes, change from baseline, intention-to-treat
Placebo (n = 16) Fluvoxamine (n = 17) P-value
Day 14 Day 42 Day 70 Day 14 Day 42 Day 70 Day 14 Day 42 Day 70
VAS Fatigue -1.3 -0.6 -0.55 -0.3 -0.4 -0.35 0.31 0.51 0.51
FFSS
Physical Domain -2.0 -3.5 -4.0 0 -2.5 0 0.31 0.40 0.12
Cognitive Domain -1.5 1.0 0 -1.0 -1.0 0 0.69 0.85 0.60
Social Domain -3.0 -3.5 -2.0 -3.0 -4.0 -1.5 0.66 0.93 0.93
MFI
G e n e r a l  F a t i g u e - 2 . 0 0000- 1 . 0 0 . 1 0 0 . 6 2 0 . 8 7
Physical Fatigue 0 0 0 0 1.0 1.0 0.92 0.73 0.44
Reduction Activity 0.5 -1.0 0 1.0 -0.5 1.0 0.20 0.56 0.13
Reduction Motivation -1.0 0 -1.0 1.0 -0.5 1.0 0.08 0.94 0.71
M e n t a l  F a t i g u e - 1 . 0 - 0 . 5 00000 . 0 6 0 . 3 5 0 . 8 9
Results are expressed as median differences in scores compared to baseline.BMC Gastroenterology 2004, 4:13 http://www.biomedcentral.com/1471-230X/4/13
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trial reported a substantial improvement in fatigue during
treatment, and a subsequent deterioration after treatment
discontinuation. It was decided to continue fluvoxamine
treatment in this patient and she has currently been free of
fatigue for two years. Her VAS scores for fatigue were 8.4
prior to treatment, 6.9 after 14 days and 2.5 after 6 weeks.
Four weeks after treatment discontinuation, her VAS score
for fatigue was 7.6.
Adverse events
Treatment was discontinued due to side effects in 5
patients in the fluvoxamine group (after 2, 5, 5, 6 and 7
days) and 2 patients (after 7 and 28 days in the placebo
group. These side effects were headache, nausea (2
patients), insomnia and dizziness (3 patients) in the flu-
voxamine group, and diarrhoea (n = 2) in the placebo
group. All side effects resolved rapidly after discontinua-
tion of the treatment and none required specific therapy
or hospitalisation.
Discussion
In the present study no beneficial effect of the antidepres-
sant drug fluvoxamine in the treatment of fatigue associ-
ated with PBC and PSC could be demonstrated. Further,
given the results of quality of life assessment, no evidence
was found for an effect on overall well being. There are
several potential explanations for the negative outcome of
this trial. The most logical would be that fatigue is neither
a symptom of a depressive disorder commonly present in
PBC and PSC nor that the aetiology of fatigue and depres-
sion are interrelated, sharing a common pathway that
could be modified by anti-depressive medications. We
believe this is the most likely explanation. Although a
high prevalence of depression has been reported in PBC
[3,12], we doubt whether this also applies to our patients
as preliminary results of an ongoing study indicate that
depression in our patients with PBC and PSC is infrequent
(study in progress). On the other hand, the trial may have
failed to detect a true therapeutic effect of fluvoxamine.
The trial was designed to detect a large treatment effect
while the number of patients that was enrolled in the
study was lower than expected. In addition, the number of
patients discontinuing treatment was higher than
expected. Therefore, a (small) beneficial effect of fluvox-
amine may well have been missed, and larger trials using
fluvoxamine or another SSRI may be needed to define the
efficacy of these drugs in the treatment of fatigue. How-
ever, the initiation of large trials in cholestatic liver disease
is particularly difficult since these diseases are relatively
rare. As a result international collaboration is usually
needed but acquiring sufficient funding for such collabo-
ration is a recurrent problem.
Although on the whole patient groups were nicely bal-
anced, the baseline scores in the cognitive and social
domains of the FFSS were higher for the fluvoxamine
group, suggesting fatigue might have been more severe in
this group. However, since all other measurements of
fatigue showed no significant differences, it appears
unlikely that bias due to differences in base-line character-
istics of the treatment groups has significantly influenced
the results. Finally, the duration of treatment may have
been too short, given the chronic character of fatigue asso-
ciated with cholestatic liver diseases. Although therapeutic
effects of fluvoxamine when used for treating depression
are in general apparent within 2–4 weeks, the possibility
that therapeutic effects may only become apparent after
more prolonged treatment cannot be excluded.
Side effects leading to discontinuation of the drug
occurred in one third of patients receiving fluvoxamine
treatment. This was much more frequent than expected
and contrasting with available data on the tolerability of
the drug. We have no clear suggestion as to a possible
explanation. The 150 mg dose we used was comparable to
those used in other studies and within the 100 – 200 mg
dose range frequently used for treating depression. This
experience raises the possibility that patients with choles-
tatic disorders are more susceptible for developing side
effects. Unfortunately, we did not monitor plasma fluvox-
amine concentrations and therefore cannot exclude the
possibility that side effects were related to higher fluvox-
amine blood concentrations as compared to those in nor-
mal individuals. In this context it should be noted that all
patients were ambulant and had relatively mild liver dys-
function. None of the side effects required intervention or
persisted after discontinuation of the drug, and there were
no obvious deteriorations in liver tests in any of the
patients. There have been no previous studies of
Visual analogue scale for fatigue Figure 2
Visual analogue scale for fatigue. Median Visual Ana-
logue Scores for fatigue. No significant differences were 
found within and between groups at entry, during treatment 
(day 14 and day 42) and 4 weeks after stopping the trial 
medication.BMC Gastroenterology 2004, 4:13 http://www.biomedcentral.com/1471-230X/4/13
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fluvoxamine or other antidepressants in the treatment of
fatigue associated with cholestatic liver diseases, but sev-
eral studies have addressed the efficacy of these drugs in
the treatment of chronic fatigue syndrome and fibromyal-
gia. According to a recent meta-analysis, antidepressants
are effective in the treatment of many of the symptoms of
fibromyalgia, including fatigue [13]. Two randomised
controlled trials, however, did not find an improvement
in patients with the chronic fatigue syndrome [14,15].
Conclusions
In conclusion, although the present study lacked power to
detect small but possibly relevant treatment effects, no
evidence for a therapeutic effect of fluvoxamine in the
treatment of fatigue associated with PBC or PSC was
found. The results may indirectly suggest that fatigue is
not a symptom of an underlying depressive disorder in
these patients with cholestatic liver disease.
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